Physician profile
Mustafa Haroon
NPI 1528473964
$5,117.08
in general payments reported to CMS, 2019-2025
28 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $135 · 2021: $402 · 2022: $742 · 2023: $1,301 · 2024: $1,696 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,838.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,013.73 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $893.74 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $478.32 | 2022-2025 | Stelara, Remicade, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $453.50 | 2020-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $376.81 | 2023-2025 | Ibsrela |
| Celgene Corporation | $287.32 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $200.81 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $162.66 | 2021-2025 | Linzess |
| Intercept Pharmaceuticals, INC. | $161.24 | 2020-2024 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $134.50 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $111.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $110.45 | 2023-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $98.08 | 2022-2024 | Dupixent |
| Qol Medical, LLC | $93.46 | 2024-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $70.73 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $66.85 | 2022-2024 | Suflave, Sutab |
| Pfizer INC. | $61.13 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $53.06 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $42.23 | 2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $38.88 | 2023 | Stelara |
| Organon LLC | $37.38 | 2023-2025 | Hadlima, Renflexis |
| Boston Scientific Corporation | $35.30 | 2022-2024 | Compliance Endokit |
| Fresenius Kabi USA, LLC | $34.17 | 2023 | Idacio |
| Ethicon US, LLC | $24.82 | 2022 | |
| Vivus LLC | $23.03 | 2024 | Qsymia |
| Nestle Healthcare Nutrition INC. | $20.59 | 2021 | |
| Redhill Biopharma INC. | $16.58 | 2020 | |
| Evoke Pharma, INC. | $16.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mustafa Haroon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.